Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyKaiser Permanente HIFU Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedKaiser PermanentePolicy N/A

    High Intensity Focused Ultrasound (HIFU) for the Treatment of Localized Prostate Cancer

    Customize your policy alerts

    Sign up for all Kaiser Permanente policy alerts

    Know when Kaiser Permanente releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This clinical review criterion governs medical-necessity determinations for HIFU used to treat localized or recurrent localized prostate cancer for Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Coverage remains subject to the member’s Evidence of Coverage and applicable plan requirements.

    Policy Summary
    PayerKaiser Permanente
    PolicyHigh Intensity Focused Ultrasound (HIFU) for the Treatment of Localized Prostate Cancer
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJanuary 1, 2027
    Last ReviewJul 7, 2026
    Next Review DateN/A
    Key ActionSubmit the required clinical notes and most recent imaging, then verify authorization requirements using the Pre-authorization Code Check.
    SourceLink
    POLICY UPDATE CHANGES

    Effective January 1, 2027, Kaiser Permanente adopted the MCG Urologic Surgery or Procedure GRG (SG-US) for medical-necessity determinations for focal subtotal image-guided prostate procedures.

    The policy changes the non-Medicare HIFU position from not medically necessary through January 1, 2027, to medically necessary when the applicable criteria are met beginning January 1, 2027.

    CPT code 55880 was added effective January 1, 2021.

    Kaiser Permanente approved new HIFU criteria based on MCG urology procedure guidelines for prostate cancer, effective January 1, 2027.

    Diagnosis codes for HIFU were removed from the applicable codes section in January 2022.

    The applicable code listing was updated in December 2024.

    01/01/2027Revised criteria effective

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2Applicable procedure codes
    0Randomized controlled trials
    60 daysNotice period
    LowEvidence quality

    Medical-Necessity Coverage Criteria

    Non-Medicare HIFU through January 1, 2027

    Effective until January 1, 2027, for non-Medicare members: HIFU is considered not medically necessary when the following applies.

    Not medically necessary during prior period: There is insufficient evidence in the published medical literature to show that this service or therapy is as safe as standard services or therapies and/or provides better long-term outcomes than current standard services or therapies.Effective until January 1, 2027

    This determination applies to non-Medicare members.

    Non-Medicare HIFU beginning January 1, 2027

    Effective January 1, 2027, for non-Medicare members, medical necessity is determined using the following criteria.

    Applicable MCG medical-necessity criteria: Medical necessity is determined using the MCG Urologic Surgery or Procedure GRG (SG-US) for focal subtotal image-guided prostate procedures.Effective January 1, 2027

    Access the MCG Clinical Guidelines criteria through the MCG Guideline Index in the provider portal under Quick Access.

    Medicare medical-necessity determination

    For Medicare members, medical necessity is determined using the following pathway.

    Use Kaiser Permanente HIFU criteria for medical-necessity determination: Because there is no active National Coverage Determination, Local Coverage Determination, Local Coverage Article, or other coverage guidance, Kaiser Permanente Health Plan of Washington has elected to use the High Intensity Focused Ultrasound (HIFU) for the Treatment of Localized Prostate Cancer criteria for medical-necessity determinations.No active NCD, LCD, or other coverage guidance

    Kaiser Permanente Medical Policy is the selected source for this determination.

    For non-Medicare members, HIFU is considered not medically necessary through January 1, 2027. The published medical literature does not establish that HIFU is as safe as standard services or therapies or that it provides better long-term outcomes than current standard treatment.

    For non-Medicare members, the coverage position transitions on January 1, 2027: HIFU may be considered medically necessary when the applicable policy or MCG criteria are met. The evidence review identified no randomized controlled trials, characterized the available evidence as low quality, and concluded that efficacy and safety for localized or recurrent localized prostate cancer could not be determined; the treatment therefore did not meet Kaiser Permanente Medical Technology Assessment Criteria at the time of review.

    HIFU services provided before January 1, 2027 are considered not medically necessary for non-Medicare members because the available evidence is insufficient to establish safety comparable to standard therapies or better long-term outcomes.

    Applicable Codes

    Applicable CodesCPT | HCPCS
    55880Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance
    C9734Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic resonance (MR) guidance
    Applicable CodesCPT | HCPCS
    55880Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance
    C9734Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic resonance (MR) guidance

    Authorization and Documentation Requirements

    Prior Authorization

    Submit Documentation and Verify Authorization

    Before requesting HIFU or the applicable focused-ultrasound prostate procedure, submit the required clinical documentation and verify authorization requirements for the specific service and plan type.

    • Applicable codes include CPT 55880 (ablation of malignant prostate tissue with HIFU) and HCPCS C9734 (focused ultrasound ablation/therapeutic intervention with MR guidance).
    • Codes may not be all-inclusive; deleted codes or codes not in effect on the date of service may not be covered.
    Prior Authorization

    Verify Authorization Requirements

    Use Kaiser Permanente's Pre-authorization Code Check to verify authorization requirements for the specific HIFU code and the member's plan type.

    Clinical Background

    High Intensity Focused Ultrasound (HIFU) is a non-ionizing ablative procedure that focuses high-energy ultrasound on prostate tissue. The focused energy produces heat, acoustic cavitation, and coagulative necrosis while attempting to spare surrounding tissue. HIFU may be used as primary or salvage treatment for localized prostate cancer.

    Key Terms

    High Intensity Focused Ultrasound (HIFU)
    ProcedureFocused ultrasound beams target localized tissue without destroying the surrounding tissue.
    Tissue effectThe high energy produced by HIFU causes coagulative necrosis through hyperthermia and acoustic cavitation.
    DeliveryA transducer is inserted into the rectum and generates precise small lesions that partially or completely destroy prostate tissue.
    Primary treatment
    Treatment roleHIFU used as the initial treatment for localized prostate cancer.
    Disease settingLocalized prostate cancer.
    Treatment category
    Policy Summary
    PayerKaiser Permanente
    PolicyHigh Intensity Focused Ultrasound (HIFU) for the Treatment of Localized Prostate Cancer
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJanuary 1, 2027
    Last ReviewJul 7, 2026
    Next Review DateN/A
    Key ActionSubmit the required clinical notes and most recent imaging, then verify authorization requirements using the Pre-authorization Code Check.
    SourceLink
    On This Page
    Medical-Necessity Coverage CriteriaApplicable CodesAuthorization and Documentation RequirementsClinical BackgroundKey Terms
    Documentation Required

    Required Clinical Documentation

    Support the medical-necessity review with the requesting provider's and/or relevant specialist's clinical documentation from the last six months.

    • Provide the most recent clinical notes from the requesting provider and/or specialist, including an oncologist, radiologist, or primary care provider.
    Billing Rule

    Apply the Date-Based Determination

    The medical-necessity determination is date-based. Services effective until January 1, 2027 are considered not medically necessary; services effective January 1, 2027 are considered medically necessary only when the criteria in the applicable policy statements are met.

    • The pre-January 1, 2027 determination reflects insufficient evidence that HIFU is as safe as standard therapy or provides better long-term outcomes.
    • Beginning January 1, 2027, apply the applicable MCG Urologic Surgery or Procedure GRG criteria for focal subtotal image-guided prostate procedures.
    Denial Risk

    Meet Applicable MCG Criteria

    For services effective January 1, 2027, Kaiser Permanente uses the MCG Urologic Surgery or Procedure GRG (SG-US) to determine medical necessity for focal subtotal image-guided prostate procedures.

    • Access the MCG Clinical Guidelines criteria through the provider portal's MCG Guideline Index under Quick Access.
    • Requests that do not meet the applicable MCG criteria may be denied.
    Denial Risk

    Service Date or Criteria Not Met

    Pre-January 1, 2027 services are considered not medically necessary. Beginning January 1, 2027, requests may be denied when the applicable MCG criteria are not met or when required documentation does not support medical necessity.

    • Confirm the service date before submitting the request.
    • Ensure the submitted clinical notes and most recent imaging support the applicable criteria.
    Primary treatment, as distinct from salvage treatment after prior therapy.
    Salvage treatment
    Treatment roleHIFU used for localized prostate cancer after prior treatment.
    Prior treatment exampleIncludes treatment after external beam radiotherapy (EBRT).
    Evidence contextHIFU as salvage therapy after EBRT was assessed in two case series.